Skip to content
Research/Metabolic Optimization/Glucagon-Like Peptide-1 Agonist (GLP-1)

Glucagon-Like Peptide-1 Agonist (GLP-1)

Glucagon-Like Peptide-1 Agonists (GLP-1) are compounds that mimic the incretin hormone GLP-1, which enhances insulin secretion and inhibits glucagon release, thereby improving blood glucose control. They are primarily used in the management of type 2 diabetes and have shown potential in weight management and cardiovascular health, making them relevant for longevity and health optimization.

Intelligence Profile

Research Papers

Recent research and clinical trials provide insights into the use of Glucagon-Like Peptide-1 (GLP-1) receptor agonists across various health conditions.

A study published in the Journal of the American College of Cardiology evaluated the cardiovascular outcomes of oral semaglutide, a GLP-1 receptor agonist, in patients with type 2 diabetes. This study highlighted significant outcomes related to the extent of vascular disease, suggesting potential cardiovascular benefits of the medication.

Another study in Endocrinology, Diabetes & Metabolism focused on dietary intake and body composition changes in Japanese individuals with type 2 diabetes using oral semaglutide. This prospective observational study provided evidence on semaglutide’s influence on diet and body composition, further supporting its application in managing type 2 diabetes.

In the realm of immunology, research published in Frontiers in Immunology discussed the role of the cytokine IL-6 in differentiating the effects of GLP-1 receptor agonists from metformin in various health conditions. This suggests a mechanistic insight that could guide personalized treatment strategies.

From a psychiatric perspective, a bibliometric analysis presented in Frontiers in Psychiatry explored research trends and collaboration networks around GLP-1 receptor agonists and psychiatric outcomes, indicating growing interest and collaboration in this intersection of endocrinology and mental health.

Regarding clinical trials, a completed pilot study (NCT01832532) explored the effects of liraglutide, another GLP-1 receptor agonist, on sleep-disordered breathing, indicating potential broader implications of GLP-1 agonists beyond metabolic syndrome.

Overall, these studies and clinical trials suggest diverse applications of GLP-1 receptor agonists in cardiovascular, metabolic, immune, and psychiatric health, with ongoing research expanding their use and understanding.

Disclaimer: This synthesis is based on specific studies and does not constitute medical advice. Always consult healthcare professionals for medical concerns.

Free account required

Research papers requires a free AXIFI account to access clinical data, safety profiles, and research papers.